Enrollment discontinued in Ph 3 KarMMa-9 study of Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients with suboptimal response after autoSCT October 2, 2024
DARZALEX FASPRO-based quadruplet regimen significantly improves MRD negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned October 1, 2024
TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) combo yields high response rates and durable responses in triple-class refractory RRMM patients October 1, 2024
Blenrep (belantamab mafodotin) combinations in R/R multiple myeloma accepted for regulatory review in Japan September 24, 2024
Blenrep (belantamab mafodotin) combination receives Breakthrough Therapy Designation in China in R/R multiple myeloma September 24, 2024
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma September 24, 2024
Sarclisa + SOC approved in the US for adult patients with newly diagnosed multiple myeloma not eligible for transplant September 24, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
New Case Study Demonstrating Reactivation of P-BCMA-101 CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma Presented September 10, 2024
FDA issues a CRL for linvoseltamab’s BLA in R/R multiple myeloma that has progressed after at least three prior therapies August 27, 2024
Sarclisa induction treatment demonstrated significantly improved PFS in patients with newly diagnosed multiple myeloma eligible for transplant August 13, 2024
DARZALEX FASPRO® (daratumumab & hyaluronidase-fihj)-based quadruplet regimen approved in the US for patients with newly diagnosed transplant-eligible multiple myeloma August 7, 2024
Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the EMA July 30, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in OS in landmark CARTITUDE-4 study July 9, 2024
100% Partial Response or Better Announced in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Ph 1b Trial June 25, 2024
Sarclisa Accepted For FDA Priority Review For The Treatment Of Transplant-Ineligible Newly Diagnosed Multiple Myeloma June 4, 2024
CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for 2L Treatment of Patients with R/R Multiple Myeloma May 1, 2024
